Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Bispecific bi-paratopic antibodies for the treatment of cancer

Project description

Bispecific antibodies against immune evasion in cancer

Cancer cells evade immune responses through various mechanisms, including downregulation of antigen presentation and upregulation of immune checkpoint molecules to suppress immune activation. They also overexpress glycans on their surface and create an immunosuppressive tumour microenvironment by recruiting regulatory T-cells and myeloid-derived suppressor cells. To activate the immune system against cancer, the ERC-funded BiParatopic project aims to develop bispecific bi-paratopic antibodies that target two distinct epitopes on immune-suppressive receptors. Researchers will test the anti-cancer efficacy of this dual epitope targeting lung cancer models. The goal is to develop novel immunotherapies against cancers that exhibit resistance to current modalities.

Objective

Immune checkpoint inhibitors have revolutionized cancer therapy, yet the majority of patients do not respond to current treatments, such as PD-1/PD-L1blockade. In non-small cell lung cancer (NSCLC), over 70% of patients experience immune evasion mechanisms that prevent effective immune activation. One such mechanism involves the overexpression of glycans on tumor cells, which can modulate immune responses. In this project, we propose to develop novel bispecific bi-paratopic antibodies that simultaneously target two distinct epitopes of the target. This innovative approach is designed to provide a more comprehensive blockade of immune-suppressive functions by dual engagement of the receptor. Our bispecific antibodies will be engineered and optimized to target different epitopes, enhancing their ability to restore immune function. The project will involve the engineering, structural characterization, and functional validation of the bispecific antibodies, followed by preclinical efficacy studies in NSCLC models. By this approach, these antibodies have the potential to overcome the limitations of existing immunotherapies, offering a new therapeutic option for cancer patients who are resistant to current treatments. In addition to the scientific development, this ERC PoC project is designed to develop a robust commercialization strategy, with the potential for patent filings and engagement with pharmaceutical partners. Our vision is to bring these bispecific antibodies to the clinic, ultimately aiming to improve outcomes for patients with NSCLC and other cancers.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE
Net EU contribution
€ 150 000,00
Address
PARQUE TECNOLOGICO EDIFICIO 801 A
48160 DERIO VIZCAYA
Spain
Region
Noreste País Vasco Bizkaia
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)